3 completed, 1 unknown. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Sen-Jam Pharmaceutical: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol Treatment A- Fexofenadine HCl 60mg, Treatment B- Naproxen sodium 220mg, Treatment C- SJP-001 280mg - Healthy | Phase 1 / Phase 2 | Completed | Sen-Jam Pharmaceutical | 47 | 2025-09-30 | 2026-03-23 |
| Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 Ketotifen/Indomethacin, Placebo - COVID-19 Respiratory Infection | Phase 3 | Completed | Sen-Jam Pharmaceutical | 150 | 2022-05-03 | 2024-06-24 |
| Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001 JMI-001, Naproxen, Fexofenadine - Veisalgia | Phase 1 | Unknown | Sen-Jam Pharmaceutical | 48 | 2017-08-01 | 2017-06-12 |
| Safety and Efficacy of a Combination Product for the Prevention of Veisalgia JMI-001 (SJP-304 and SJP-223), SJP-304, SJP-223 - Veisalgia | Phase 2 | Completed | Sen-Jam Pharmaceutical | 13 | 2016-03-01 | 2018-07-19 |
Indomethacin (1) · Ketotifen (1) · Naproxen (1) · fexofenadine (1) · ketotifen fumarate ophthalmic solution (1)
Canada (1) · Nepal (1)
Alexander T Limkakeng, MD (1) · Jackie Iversen (1) · Magdy L Shenouda (1) · Magdy L Shenouda, MD (1)